New drug duo aims to shrink lung tumors before surgery
NCT ID NCT07269782
Summary
This study is testing a new two-drug combination (HLX43 plus serplulimab) given to patients before they have surgery for non-small cell lung cancer. The goal is to see if this treatment can shrink or eliminate the tumor to make surgery more effective. The study will enroll 60 adults with stage II-IIIB lung cancer who have not had prior cancer treatment and are eligible for surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.